Figure 5.
An AIP-1 human homologue, AIRAPL, has a protective effect against Aβ42 toxicity and AIP-1 putative farnesylation site is essential for its protective effect against Aβ42 toxicity. (A) The paralysis phenotype of Aβ42-expressing animals is delayed by human AIRAPL overexpression. (B) Human AIRAP overexpression had no effect on the paralysis phenotype of Aβ42-expressing animals. (C) Deleting the C-terminal two residues in AIP-1 disrupts its putative isoprenylation site and abolishes its protective effect. Error bars represent the SEM. The P-values shown were obtained using a two-way ANOVA.